REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by Mizuho

by · The Cerbat Gem

REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by analysts at Mizuho to a “strong-buy” rating in a research note issued on Monday, Zacks reports.

Other research analysts have also issued reports about the stock. Wall Street Zen raised shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Robert W. Baird cut their price objective on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a research note on Tuesday, August 25th. Barclays cut REGENXBIO from an “overweight” rating to a “hold” rating in a report on Friday, August 7th. Morgan Stanley restated an “overweight” rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Friday, August 7th. Finally, Zacks Research raised REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $23.17.

Check Out Our Latest Research Report on RGNX

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $7.45 on Monday. The company has a fifty day moving average of $9.18 and a two-hundred day moving average of $9.11. The stock has a market capitalization of $491.77 million, a PE ratio of -1.97 and a beta of 1.13. REGENXBIO has a fifty-two week low of $5.45 and a fifty-two week high of $16.19.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. Research analysts forecast that REGENXBIO will post -3.91 earnings per share for the current year.

Institutional Trading of REGENXBIO

A number of hedge funds have recently bought and sold shares of RGNX. BlackRock Inc. purchased a new position in REGENXBIO in the 2nd quarter worth approximately $76,641,000. Dimensional Fund Advisors LP grew its position in shares of REGENXBIO by 11.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,010,381 shares of the biotechnology company’s stock valued at $8,464,000 after purchasing an additional 106,530 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of REGENXBIO in the second quarter valued at approximately $6,212,000. Corient Private Wealth LP acquired a new stake in shares of REGENXBIO in the second quarter valued at approximately $2,608,000. Finally, Deutsche Bank AG acquired a new stake in shares of REGENXBIO in the second quarter valued at approximately $2,490,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

(Get Free Report)

REGENXBIO Inc is a biotechnology company focused on developing and commercializing gene therapies for serious diseases. The company’s programs are based primarily on its proprietary NAV AAV Technology Platform, which uses adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells. Its research has emphasized conditions affecting the central nervous system, muscles and other tissues.

REGENXBIO’s pipeline has included investigational therapies such as RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I and RGX-202 for Duchenne muscular dystrophy.

See Also